Tissue | Expression Dynamics | Abbreviation |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/DPP4_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DPP4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DPP4_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DPP4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0070482113 | Thyroid | PTC | response to oxygen levels | 167/5968 | 347/18723 | 1.51e-10 | 5.03e-09 | 167 |
GO:0036293113 | Thyroid | PTC | response to decreased oxygen levels | 153/5968 | 322/18723 | 2.71e-09 | 7.52e-08 | 153 |
GO:0001666113 | Thyroid | PTC | response to hypoxia | 145/5968 | 307/18723 | 1.14e-08 | 2.74e-07 | 145 |
GO:0052126113 | Thyroid | PTC | movement in host environment | 91/5968 | 175/18723 | 2.41e-08 | 5.43e-07 | 91 |
GO:0001667112 | Thyroid | PTC | ameboidal-type cell migration | 198/5968 | 475/18723 | 3.36e-06 | 4.34e-05 | 198 |
GO:0044409113 | Thyroid | PTC | entry into host | 72/5968 | 151/18723 | 3.48e-05 | 3.29e-04 | 72 |
GO:0010631111 | Thyroid | PTC | epithelial cell migration | 149/5968 | 357/18723 | 4.83e-05 | 4.33e-04 | 149 |
GO:0090132111 | Thyroid | PTC | epithelium migration | 149/5968 | 360/18723 | 7.89e-05 | 6.74e-04 | 149 |
GO:0046718112 | Thyroid | PTC | viral entry into host cell | 68/5968 | 144/18723 | 8.26e-05 | 7.00e-04 | 68 |
GO:0045785112 | Thyroid | PTC | positive regulation of cell adhesion | 176/5968 | 437/18723 | 1.10e-04 | 8.83e-04 | 176 |
GO:0090130111 | Thyroid | PTC | tissue migration | 150/5968 | 365/18723 | 1.13e-04 | 9.01e-04 | 150 |
GO:00301986 | Thyroid | PTC | extracellular matrix organization | 124/5968 | 301/18723 | 3.75e-04 | 2.53e-03 | 124 |
GO:00430626 | Thyroid | PTC | extracellular structure organization | 124/5968 | 302/18723 | 4.38e-04 | 2.92e-03 | 124 |
GO:00452296 | Thyroid | PTC | external encapsulating structure organization | 124/5968 | 304/18723 | 5.96e-04 | 3.79e-03 | 124 |
GO:19030533 | Thyroid | PTC | regulation of extracellular matrix organization | 26/5968 | 48/18723 | 1.13e-03 | 6.59e-03 | 26 |
GO:004354219 | Thyroid | PTC | endothelial cell migration | 112/5968 | 279/18723 | 2.03e-03 | 1.09e-02 | 112 |
GO:007169216 | Thyroid | PTC | protein localization to extracellular region | 139/5968 | 368/18723 | 8.95e-03 | 3.72e-02 | 139 |
GO:000930618 | Thyroid | PTC | protein secretion | 135/5968 | 359/18723 | 1.16e-02 | 4.58e-02 | 135 |
GO:003559218 | Thyroid | PTC | establishment of protein localization to extracellular region | 135/5968 | 360/18723 | 1.28e-02 | 4.95e-02 | 135 |
GO:001603234 | Thyroid | ATC | viral process | 241/6293 | 415/18723 | 5.50e-25 | 2.04e-22 | 241 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DPP4 | SNV | Missense_Mutation | novel | c.1444N>A | p.Leu482Ile | p.L482I | P27487 | protein_coding | deleterious(0.05) | benign(0.258) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DPP4 | SNV | Missense_Mutation | rs755540270 | c.1051N>G | p.Thr351Ala | p.T351A | P27487 | protein_coding | deleterious(0.02) | benign(0.112) | TCGA-AR-A2LK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | anastrozole | PD |
DPP4 | SNV | Missense_Mutation | | c.1394N>T | p.Ala465Val | p.A465V | P27487 | protein_coding | deleterious(0.01) | possibly_damaging(0.675) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
DPP4 | SNV | Missense_Mutation | | c.2222N>A | p.Gly741Glu | p.G741E | P27487 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-B6-A0X1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
DPP4 | SNV | Missense_Mutation | | c.779N>C | p.Gly260Ala | p.G260A | P27487 | protein_coding | deleterious(0.01) | probably_damaging(0.928) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
DPP4 | SNV | Missense_Mutation | novel | c.1493N>T | p.Ser498Leu | p.S498L | P27487 | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
DPP4 | SNV | Missense_Mutation | rs752793888 | c.1067N>A | p.Arg356Lys | p.R356K | P27487 | protein_coding | tolerated(0.52) | benign(0.084) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DPP4 | SNV | Missense_Mutation | | c.67N>A | p.Val23Met | p.V23M | P27487 | protein_coding | tolerated(0.16) | probably_damaging(0.988) | TCGA-D8-A1XM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DPP4 | deletion | Frame_Shift_Del | rs779957190 | c.135_138delAACT | p.Thr46IlefsTer3 | p.T46Ifs*3 | P27487 | protein_coding | | | TCGA-A2-A3XW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamyicin | CR |
DPP4 | SNV | Missense_Mutation | | c.2072N>C | p.Arg691Thr | p.R691T | P27487 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL2105762 | OMARIGLIPTIN | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | VILDAGLIPTIN | VILDAGLIPTIN | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | Beta-phe compound 2 | | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | Imidazo cyclohexylamine derivative 3 | | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | Peptide analog 47 | | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | ENALAPRIL | ENALAPRIL | 16678199 |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | Dutogliptin | DUTOGLIPTIN | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL3833357 | BEGELOMAB | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | inhibitor | 363894186 | TALABOSTAT | |
1803 | DPP4 | PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | PMID25482888-Compound-52 | | |